
|Videos|March 4, 2021
Find out more about Allergan’s presbyopia drop NDA filing
Potential presbyopia treatment coming
Advertisement
Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Crafting your own eyewear brand: An introduction to LFVR Eyewear and how to get started
4
Optometric and ophthalmic forces unite at EyeCon 2025
5

















































.png)


